1 INN Class Route (list ) PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) Primary Target and PDB code of Protein-Drug complex Targets from DrugCentral Links
CLOPIDOGREL (has an active metabolite )
CLOPIDOGREL ATC B01AC04
BLOOD ANTICOAGULANT PLATELET AGGREGATION INHIBITOR ANTITHROMBOTIC ANTIANGINAL FIBRINOLYTIC AGENTS TREATMENT OF ACUTE CORONARY SYNDROME, MYOCARDIAL INFARCTION, STROKE ACTION THROUGH IRREVERSIBLE BINDING OF ITS METABOLITE
ORAL Cmax 7.7 NANOMOLAR
Tmax 0.75 HOUR
F 50 PERCENT
PPB 98 PERCENT
HT 6 HOUR
SOLUBILITY PRACTICALLY INSOLUBLE IN WATER AT NEUTRAL PH BUT FREELY SOLUBLE AT PH 1
P2Y PURINOCEPTOR 12 PDB 3ME6 (CRYSTAL STRUCTURE OF CYTOCHROME 2B4 IN COMPLEX WITH THE ANTI-PLATELET DRUG CLOPIDOGREL)
LIGAND CODE = CGE (link to the list of PDB complexes)
Download experimental 3D coordinates of CGE with added hydrogens
PURINERGIC RECEPTOR P2Y12 ANTAGONIST CHEMBL2001 PURINERGIC RECEPTOR P2Y12 Q9H244 P2Y PURINOCEPTOR 12 HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL NUCLEOTIDE-LIKE RECEPTOR PURINE RECEPTOR ANSM (in French) Dailymed Drugs.com
SIDER side effects
Chemical Probes Portal
ChEMBL BindingDB DrugBank
2 INN Class Route (list ) PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) Primary Target and PDB code of Protein-Drug complex Targets from DrugCentral Links
M CLOPIDOGREL (is an active metabolite )
CLOPIDOGREL ATC B01AC04
BLOOD ANTICOAGULANT PLATELET AGGREGATION INHIBITOR ANTITHROMBOTIC ANTIANGINAL FIBRINOLYTIC AGENTS TREATMENT OF ACUTE CORONARY SYNDROME, MYOCARDIAL INFARCTION, STROKE ACTION THROUGH IRREVERSIBLE BINDING OF ITS METABOLITE
- Cmax 64.7 NANOMOLAR (300 MILLIGRAM)
Tmax 0.75 HOUR
HT 0.5 HOUR
P2Y PURINOCEPTOR 12
PURINERGIC RECEPTOR P2Y12 ANTAGONIST CHEMBL2001 PURINERGIC RECEPTOR P2Y12 Q9H244 P2Y PURINOCEPTOR 12 HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL NUCLEOTIDE-LIKE RECEPTOR PURINE RECEPTOR ANSM (in French) Dailymed Drugs.com
SIDER side effects
Chemical Probes Portal
ChEMBL BindingDB DrugBank
3 INN Class Route (list ) PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) Primary Target and PDB code of Protein-Drug complex Targets from DrugCentral Links
M CLOPIDOGREL (is an active metabolite )
CLOPIDOGREL ATC B01AC04
BLOOD ANTICOAGULANT PLATELET AGGREGATION INHIBITOR ANTITHROMBOTIC ANTIANGINAL FIBRINOLYTIC AGENTS TREATMENT OF ACUTE CORONARY SYNDROME, MYOCARDIAL INFARCTION, STROKE ACTION THROUGH IRREVERSIBLE BINDING OF ITS METABOLITE
- Cmax 64.7 NANOMOLAR (300 MILLIGRAM)
Tmax 0.75 HOUR
HT 0.5 HOUR
P2Y PURINOCEPTOR 12
PURINERGIC RECEPTOR P2Y12 ANTAGONIST CHEMBL2001 PURINERGIC RECEPTOR P2Y12 Q9H244 P2Y PURINOCEPTOR 12 HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL NUCLEOTIDE-LIKE RECEPTOR PURINE RECEPTOR ANSM (in French) Dailymed Drugs.com
SIDER side effects
Chemical Probes Portal
ChEMBL BindingDB DrugBank